Organised by European Science Foundation (ESF), the FET Flagship pilot project IT Future of Medicine (ITFoM) and Max Planck Institute for Molecular Genetics in cooperation with the Institute for Public Health Genomics (IPHG) at Maastricht University
Sponsored by AMGEN and Pfizer
Personalised medicine and healthcare call for appropriate governance strategies at the European and global level as they challenge the way in which healthcare systems worldwide are set up. Policy makers and the many other stakeholders have to interact and discuss medium- to long-term views and provide timely policy advice that will help prepare Europe for the likely changes in how society deals with wellbeing, health, healthy ageing, healthy diet, and disease. Such a European agenda may lead the way for a global personalized medicine.
A Forward Look on personalised medicine
S Berghmans, Director, Centre d’Innovation Médicale, and former Head, Biomedical Sciences Unit, European Science Foundation
Addressing global health challenges through research collaboration: the examples of ITFoM and BBMRI
K Zatloukal, Professor, Medical University Graz, Austria
The importance of molecular testing to ensure personalised medicine uptake – the role of Public Private Partnership
A Penk, Regional President Oncology Europe, Pfizer
Is there a global approach to personalised medicine?
R Wells, former Head Biotechnology Unit, Directorate for Science, Technology and Industry, OECD
How can new systems biology make effective impact on global health concerns?
W Christie, Chairman, World Health Connections, Norway
Improving patient care by enabling access to personalised medicine in Europe
J Bowis, Co-chair, European Alliance for Personalised Medicine
A new community-based vision of open access innovation in personalised medicine
S Friend, President, Sage Bionetworks, USA
A Brad, Professor, Institute for Public Health Genomics (IPHG), Maastricht University
R Sudbrak, Scientific Coordination and Management, Max Planck Institute for Molecular Genetics